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A B S T R A C T
Background: Several studies reported beneficial effects of chromium supplementation for management of type 2 
diabetes mellitus (T2DM). The present study aimed to provide a systematic review and meta-analysis of ran-
domized controlled trials (RCTs) examining the effects of chromium supplementation on blood pressure, body 
mass index (BMI), liver function enzymes and malondialdehyde (MDA) in patients with T2DM. 
Methods: PubMed, Scopus, and Embase were searched up to 15 November 2020 with no language and time 
restriction. RCTs that reported the effects of chromium supplementation on blood pressure, BMI, liver function 
enzymes and MDA in patients with T2DM were included. A random-effects model was used to compute weighted 
mean differences (WMDs) with 95 % confidence intervals (CIs). Between-study heterogeneity was assessed by 
Cochran’s Q test and quantified by I2 statistic. 
Results: Of 3586 publications, 15 RCTs were included for the meta-analysis. Pooled effect sizes indicated that 
chromium significantly reduced diastolic blood pressure (DBP) (WMD): -2.36 mmHg, 95 % CI: − 4.14, − 0.60; P =
0.008), and MDA (WMD: − 0.55 umol/l, 95 % CI: − 0.96, − 0.14; P = 0.008). However, chromium supplemen-
tation did not significantly affect BMI, systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST). Meta-regression analysis did not show significant linear relationship between dose of 
chromium and change in BMI (p = 0.412), SBP (p = 0. 319), DBP (p = 0.102), ALT (p = 0.923), AST (p = 0.986) 
and MDA (p = 0.055). 
Conclusion: The present systematic review and meta-analysis shows that supplementation with chromium at dose 
of 200–1000 μg/day may reduce DBP and MDA in T2DM patients.   
Abbreviations: RCTs, randomized controlled trials; SBP, systolic blood pressure; DBP, diastolic blood pressure; MDA, malondialdehyde; BMI, body mass index; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; WMD, Weighted Mean Difference; T2DM, type 2 diabetes mellitus; PTP1B, protein tyrosine 
phosphatase 1B; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis; MeSH, medical subject heading; CI, confidence interval. 
* Corresponding author at: Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
E-mail addresses: omid.asbaghi@gmail.com (O. Asbaghi), DR.fnaeeni@gmail.com (F. Naeini), Damoon_ashtary@yahoo.com (D. Ashtary-Larky), Mojtaba.
kaviani@acadiau.ca (M. Kaviani), m.rezaei81@yahoo.com (M. Rezaei Kelishadi), islampoor.eli@gmail.com (E. Eslampour), sajadmoradi9096@gmail.com 
(S. Moradi), ad0183@coventry.ac.uk (C.C.T. Clark), am.alavi@nutr.mui.ac.ir (A.A. Naeini).  
Contents lists available at ScienceDirect 
Complementary Therapies in Medicine 
journal homepage: www.elsevier.com/locate/ctim 
https://doi.org/10.1016/j.ctim.2021.102755 
Received 15 October 2020; Received in revised form 10 May 2021; Accepted 21 June 2021   
Complementary Therapies in Medicine 60 (2021) 102755
2
1. Introduction 
Diabetes mellitus is a metabolic disease with a high financial and 
social burden on the health care system.1 The prevalence of type 2 
diabetes mellitus (T2DM) have been steadily increasing over the past 
few decades. Chronic hyperglycemia is associated with the risk of car-
diovascular complications and induces a wide range of acute negative 
effects such as blindness, ketoacidosis, and renal failure.2 There are also 
some negative chronic effects such as liver abnormalities.3 In order to 
fight T2DM complications have been suggested, various methods such as 
diet, physical activity, and dietary supplements.4,5 It has been hypoth-
esized that dietary supplements have led to noted results in improve-
ment of T2DM.6–10 
Chromium is a trace element widely distributed in the earth’s crust 
which participates in carbohydrate and lipid metabolism and could have 
a beneficial effect on body composition.11 Recently, our meta-analysis of 
23 randomized controlled trials (RCTs) showed that chromium supple-
mentation significantly improved fasting plasma glucose (FPG), insulin, 
hemoglobin A1C (HbA1C) and homeostatic model assessment for insulin 
resistance (HOMA-IR) in patients with T2DM.6 Since chronic hyper-
glycemia is the primary cause of various diabetic complications, hypo-
glycemic supplements such as chromium may improve T2DM 
complications. However, the effects of chromium supplementation in 
these complications such as hypertension, oxidative stress and liver 
function are unclear. 
Hypertension is common among patients with T2DM 12 and is 
associated with a higher risk of mortality in these populations.13 There 
are some controversies about the effects of chromium supplementation 
on blood pressure. It has been reported that low plasma chromium was 
connected with high blood pressure in patients with T2DM.14 Further-
more, some studies have reported that chromium supplementation may 
improve blood pressure levels.15,16 For instance, Farrokhian et al. 
exposed that a 12-week supplementation of chromium in diabetic pa-
tients had beneficial effects on diastolic blood pressure (DBP).17 How-
ever, some studies failed to demonstrate such effects.18,19 
It is thought that oxidative stress plays important role in the devel-
opment of vascular complications in T2DM.20 Malondialdehyde (MDA) 
assay is the most widely used lipid peroxidation technique 21 which can 
be used as an indicator for oxidative stress in patients with T2DM.22 
Moreover, a significant positive correlation has been reported between 
plasma MDA levels and FPG in T2DM.23 
It is well established that patients with T2DM have a high prevalence 
of liver disease.24–26 Diabetic patients have a higher incidence of liver 
function abnormalities than individuals who do not have diabetes.3 
Since, the literature has emerged that offers contradictory findings about 
the effects of chromium supplementation on liver function, it seems 
necessary to evaluate dietary intake changes following chromium sup-
plementation. Therefore, the aim of this study was to conduct a sys-
tematic review and meta-analysis of the pooled data from controlled 
trials to evaluate the effect of chromium supplementation on blood 
pressure, oxidative stress, liver enzymes and body mass index (BMI) in 
T2DM patients. 
2. Methods 
2.1. Literature search and selection 
This systematic review and meta-analysis was performed based on 
the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guideline.27 Relevant studies published up to 15 November 
2020 were searched through PubMed, Scopus and Embase databases 
using the following terms: ("chromium", "chromium picolinate" and 
"chromium nicotinate") and ("Type 2 diabetes mellitus", "T2DM", "dia-
betes","insulin-independent diabetes", "insulin resistance", "diabetic pa-
tients") and ("metabolic", "oxidative stress" and "malondialdehyde", 
"blood pressure", "diastolic blood pressure" and "systolic blood pressure", 
"weight", "body mass" and "body mass index", "BMI", and "body 
composition"). A first decision was made based on titles and abstracts. 
For studies that appear to meet the inclusion criteria, or in cases when a 
definite decision cannot be made based on the title and/or abstract 
alone, the full paper should be obtained for detailed assessment against 
the inclusion criteria. No limitations of language or time of publication 
were used. To avoid missing any publication, electronic database sys-
tematic searches were completed along with reference lists and citation 
hand searches. If the amount of information reported about a study was 
insufficient to make a decision about inclusion, and we contacted study 
authors to ask for more details. Unpublished data and grey kinds of 
literature, including dissertations, congresss abstracts, and patents, were 
not included in this meta-analysis. Besides, we removed duplicate cita-
tions. PRISMA diagnostic test accuracy guideline 28 were mentioned in 
supplementary file 1. 
2.2. Eligibility criteria 
The following data were extracted by two independent reviewers 
(OA and EE). The Participant, Intervention, Comparison, Outcomes, and 
Studies (PICOS) framework was used for this systematic review and 
meta-analysis. Briefly, included studies involved patients with T2DM. 
The interventions included RCTs that had a pre-post design and reported 
outcomes of a chromium supplementation intervention greater than two 
weeks. Comparison groups consisted of patients with T2DM receiving 
placebo. The primary outcomes specified for the meta-analysis were 
MDA, BP and liver enzymes. Secondary outcomes were BMI. In the case 
of many publications with the same data set, we considered only the 
most complete one. we have excluded Studies that: (1) were conducted 
on animal models, pregnant or lactating women, (2) did not have a 
random allocation, (3) did not have any comparing control group. 
Controversies about the study selection process were solved by 
discussion. 
According to the eligibility criteria, we included studies that had 
well-defined RCTs which reported at least one of the following primary 
outcome measures: MDA and BP; or secondary outcomes: liver enzymes 
and BMI. 
2.3. Quality assessment of studies 
The risk of bias for the considered studies was examined using the 
Cochrane quality assessment tool for RCTs.29 Two investigators (EE and 
BN) partly evaluated the methods and the quality of the included studies 
through Cochrane Collaboration’s tools. Cochrane Collaboration’s tools 
for quality evaluation of studies including the following seven criteria: 
1) random sequence generation; 2) allocation concealment; 3) blinding 
of participants and personnel; 4) blinding of outcome assessment; 5) 
incomplete outcome data; 6) selective reporting, and 7) other sources of 
bias. To assess the quality of studies, each study was assigned a label 
(yes, no or unclear) demonstrating it was considered low risk, high risk 
or unknown risk of bias, respectively.29 
2.4. Data extraction 
Standardized data extraction forms provided for reducing bias and 
improving validity and reliability. The following data were gathered 
from each study: first author’s name, year of publication, study location, 
study duration, mean age and gender of participants partly by inter-
vention and control groups, study design, health status of the popula-
tion, type of diet, number of participants in each group, Dose of 
chromium, and mean and SD of mentioned variables at baseline, end of 
study and/or changes between baseline and post-intervention. In cases 
of lack of pertinent data, we notified the corresponding authors to 
receive their help. Data extraction of eligible studies was performed 
independently by EE and BN using a pre-determined extraction form. 
Any discrepancies were resolved by consensus or by consultation with a 
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third reviewer (OA). 
2.5. Meta-analysis of data 
To analyze the effect size for BMI, blood pressure, oxidative stress 
and, liver enzymes the mean change and its standard deviation for 
intervention and non-intervention groups as comparison groups were 
extracted. A random-effects model was used to compute weighted mean 
differences (WMDs) with 95 % confidence intervals (CIs). Between- 
study heterogeneity was assessed by Cochran’s Q test and quantified 
by I2 statistic. Between subgroup, heterogeneity was examined using a 
fixed-effect model. Sensitivity analysis was performed by eliminating 
each study one by one and recalculating the pooled assessments. Egger’s 
regression asymmetry tests were conducted for identifying potential 
publication bias. Any publication bias was identified by the ‘trim and 
fill’ test.30 Meta-regression analysis was conducted to evaluate the as-
sociation between pooled effect size and chromium dose (μg /day).31 
Statistical analysis was performed using STATA, version 11.2 (Stata 
Corp, College Station, TX). The statistical significant value was 
explained as P values <0.05. 
3. Results 
3.1. Study selection 
We found 3586 publications in our initial search; 1448 duplicates 
were identified and removed. Out of the remaining 2138 articles, 1382 
were identified as unrelated after reviewing for titles and abstracts. 
Additional 365 papers were excluded due to animal studies and 370 
papers due to review studies. When investigating full texts of articles, 6 
papers were excluded due to a lack of reporting of desire data. Finally, 
15 trials 15,16,32–44 were included in this meta-analysis (Fig. 1). From 
these 15 trials, 6 studies evaluate the effects of chromium supplemen-
tation on BP, 9 studies determined the effect of chromium on BMI. 
Moreover, 3 and 7 studies evaluate the effects of chromium intake on 
liver enzymes and MDA respectively. 
3.2. Feature of studies 
Overall, 15 RCTs, published between 2001 and 2020, were included 
in our Meta-analysis, characteristics of the 15 randomized clinical 
trials,15,16,32–43,45 are reported in Table 1. These studies included a total 
of 806 participants (428 intervention and 378 control) aged ≥18 years. 
Fig. 1. Flowchart of study selection for inclusion trials in the systematic review.  
















Means Age Means BMI Intervention Sample 
Size 
Study results 
IG CG IG CG Treatment group Chromium dose 
(μg) 
control IG CG IG CG 




HH Cheng 2004 Taiwan parallel G1: 
20: 14 M, 6F 
G2: 
21: 9 M, 12 F 
25 IG1: 
52.5 ± 6.63 
IG2: 
53.1 ± 6.63 
CG1: 
50.8 ± 6.9 
CG2: 
50.5 ± 6 
IG1: 
27.3 ± 2.32 
IG2: 
25.9 ± 2.32 
CG1: 
























M Vrtovec 2005 USA Cross-over 60: M/F 12 NR NR 29.9 ± 3.6 30.9 ± 5.2 chromium picolinate 1000 Placebo 30 30 BMI: -0.4 ±
3.45 
SBP: -4 ± 22.64 
DBP: -4 ± 11 
BMI: -0.3 ±
5.01 
SBP: -1 ± 23.06 
DBP:-6 ± 7 
J Racek 2006 Denmark parallel 36: 9 M, 27F 12 60.8 ± 7.5 61.8 ±
10.7 
33.59 ± 5.6 35.16 ±
6.55 








N Kleefstra 2006 Netherlands parallel IG1: 
31: 14 M, 
17F 
IG2: 
32: 15 M, 
17F 
25 IG1: 
60 ± 8.8 
IG2: 
59 ± 6.4 
62 ± 7.5 IG1: 
35 ± 7.2 
IG2: 
33 ± 4.2 













BMI: 0.2 ± 1.1 
SBP: -7 ± 15 
DBP: -4 ± 11 
IG2: 
BMI: 0.2 ± 1 
SBP: -1 ± 21 
DBP: 0 ± 11 
BMI:0 ± 0.7 
SBP: -7 ± 19 
DBP: -6 ± 7 
N Kleefstra 2007 Netherlands parallel 57: 35 M, 22 
F 
25 68 ± 8.2 66 ± 8.6 30 ± 5.9 30 ± 5.6 chromium yeast 400 Placebo 29 28 BMI: 0.1 ±
0.85 
SBP: 6 ± 17 
DBP: 0 ± 9 
BMI: 0.4 ± 0.9 
SBP: 9 ± 15 
DBP: 3 ± 8 




























SBP: -8 ± 22.35 
DBP: 2 ± 12.01 




SK Jain 2012 USA parallel IG1: 
50: 9 M, 41F 
IG2: 
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Means Age Means BMI Intervention Sample 
Size 
Study results 
IG CG IG CG Treatment group Chromium dose 
(μg) 




YL Chen 2013 Taiwan parallel 66: 43 M, 
23f 

























A Farrokhian 2019 Iran parallel 64: 32 M, 32 
F 
12 58 ± 8 60.9 ± 7.7 30.4 ± 4.3 29.9 ± 3.8 chromium picolinate 200 Placebo 32 32 BMI: -0.4 ±
4.20 










MDA: 0 ± 0.55 




Abbreviations: IG, intervention group; CG, control group; NR, not reported; F, Female; M, Male; NR, not reported. 
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All studies were done on both genders. Three studies were performed in 
the United States,32,34,40 three in Taiwan,15,33,37 four in Iran,41–43,45 two 
in Netherlands,16,36 one in Denmark,35 one in Poland 38 and one in 
India.39 12 studies had parallel design,15,16,32,33,35–37,39–44 and 2 were 
crossover studies.34,38 The intervention period in the included RCTs 
varied from 8 38 to 25 16,32,33,36,37 weeks. All studies have been con-
ducted on people with type 2 diabetes, the study population of Farro-
khian et al., in addition to type 2 diabetes, also had Coronary Heart 
Disease.43 In terms of supplement type, in 6 studies chromium yeast, 
33,35–39 7 studies chromium picolinate,16,34,40–44 one study chromium 
chloride,15 one study chromium pidolate 32 and in one arm of Jain et al., 
study chromium dinicocysteinate 40 have been prescribed. Daily rec-
ommended dosage of chromium in the included RCTs varied between 
200 and 1000 μg/day. 
3.3. Quality assessment 
All included RCTs mentioned random sequence generation. In 
related with allocation concealment, 3 trials 15,33,34 had high-risk of 
bias, 6 trials,16,36,38–40,43 had low-risk of bias and other studies 
32,35,37,41,42,44 had unclear-risk of bias. Most of included trials showed 
low risk of bias regarding selective reporting.15,16,33–36,38–44 However, 
two studies 32,37 showed high-risk of bias. All of the included studies 
were mentioned blinding of participants.15,16,32–44 However, in related 
with blinding of outcome assessment was unclear in 9 stud-
ies.16,34–38,41–43 The risks of bias assessment were illustrated in Table 2. 
3.4. Effect of Chromium supplementation on blood pressure 
Totally, 6 eligible studies with 7 effect sizes, including a total of 327 
participants (intervention = 170, control = 157), examined the effect of 
chromium intake on blood pressure.34,36,39,42,43,46 Combining their 
findings based on random-effects model, we found that chromium sup-
plementation had no significant effect on SBP (Weighted Mean Differ-
ences (WMD): -1.83 mmHg, 95 % CI: -4.09, 0.42; P = 0.111) compared 
to the control group, with no significant between-study heterogeneity (I2 
= 0.0 %, P = 0.793) (Fig. 2A, Table 3). Pooled effect sizes indicated that 
chromium significantly reduced DBP (WMD: -2.36 mmHg, 95 % CI: 
-4.13, -0.60; P = 0.008) compared to placebo and without significant 
heterogeneity (I2: 21.1 %, p = 0.268) (Fig. 2B, Table 3). 
3.5. Effect of chromium supplementation on BMI 
The impact of Chromium supplementation on BMI was assessed in 9 
trials with 10 treatment arms including 429 participants (intervention =
227, control = 202). The pooled estimates demonstrate that supple-
mentation with Chromium did not cause a significant decrease in BMI 
(WMD: 0.08 kg/m2, 95 % CI: -0.15, 0.31; P: 0.498), with no evidence of 
significant between-study heterogeneity (I2: 0.0 %, P = 0.662) (Fig. 2C, 
Table 3). 
3.6. Effect of Chromium supplementation on liver enzymes 
Combining 4 effect sizes from 3 studies for ALT 37,40,47 including 160 
participants (intervention = 227, control = 203) and 3 effect sizes from 
2 studies for AST37,40 including 94 participants (intervention = 59, 
control = 35), show that supplementation with Chromium did not have 
a significant effect on plasma levels of ALT (WMD: 2.11 u/l, 95 % CI: 
-0.69, 4.91; P: 0.141) with a significant between-study heterogeneity (I2: 
74.3 %, P = 0.009) (Fig. 2D, Table 3) and AST (WMD: -0.42 u/l, 95 % CI: 
-1.39, 0.55; P: 0.395) without any between-study heterogeneity (I2: 0.0 
%, P = 0.630) (Fig. 2E, Table 3). 
3.7. Effect of Chromium supplementation on malondialdehyde 




























































































































































































































































































































































































O. Asbaghi et al.                                                                                                                                                                                                                                
Complementary Therapies in Medicine 60 (2021) 102755
7
363 patients (intervention = 183, control = 180) provided data on the 
effects of chromium on MDA, based on findings, significant changes 
were observed in MDA following the chromium supplementation 
(WMD: -0.55 umol/l, 95 % CI: -0.96, -0.14; P = 0.008) with significant 
between-study heterogeneity (I2:95.0 %, p < 0.001) (Fig. 2F, Table 3). 
3.8. Publication bias 
Egger’s regression test indicated no publication bias for BMI (p =
0.282), SBP (p = 0.390), DBP (p = 0.057), AST (p = 0.764), However, 
there was significant publication bias for ALT (P = 0.044) and MDA (P =
0.013). Due to, significant publication bias, we conducted the trim and 
fill sensitivity analysis, which was calculated from hypothesized nega-
tive unpublished studies. Therefore, results would not be changed if 4 
new trials were published regarding chromium supplementation effects 
on ALT (WMD: 2.11 u/l, 95 % CI: -0.69, 4.91; P = 0.141). However, 
MDA values could be changed if an additional 3 unpublished studies 
were added; the trim and fill analysis findings changed results to (− 0.84 
umol/l, 95 % CI: -1.24, -0.44, p < 0.001). 
3.9. Sensitivity analysis 
The results of the sensitivity analysis showed that, after the omission 
of each study, the overall results for SBP, BMI, AST, and MDA did not 
change. However, by removing study of Kalbasi et al. the overall results 
for DBP was significantly changed (WMD): -1.78 mmHg, 95 % CI: -4.07, 
0.50), and also, by removing studies by Lai et al. (WMD: 3.09 u/l, 95 % 
CI: 0.20, 5.99) and Chen et al. (WMD: 3.01 u/l, 95 % CI: 0.68, 5.35) the 
overall results for ALT was significantly changed. 
3.10. Meta-regression analysis 
We performed a meta-regression analysis to investigate the potential 
association between a decrease in BMI, SBP, DBP, AST, ALT, and MDA 
Fig. 2. A. Forest plot detailing WMDs and 95 % CIs for the effect of chromium supplementation on systolic blood pressure compared with control groups. B. Forest 
plot detailing WMDs and 95 % CIs for the effect of chromium supplementation on diastolic blood pressure compared with control groups. C. Forest plot detailing 
WMDs and 95 % CIs for the effect of chromium supplementation on body mass index compared with control groups. D. Forest plot detailing WMDs and 95 % CIs for 
the effect of chromium supplementation on alanine aminotransferase compared with control groups. E. Forest plot detailing WMDs and 95 % CIs for the effect of 
chromium supplementation on aspartate aminotransferase compared with control groups. F. Forest plot detailing WMDs and 95 % CIs for the effect of chromium 
supplementation on malondialdehyde compared with control groups. 
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and dose of chromium supplementation (μg/day). Meta-regression 
analysis did not show significant linear relationship between dose of 
chromium and change in BMI (p = 0.412), SBP (p = 0. 319), DBP (p =
0.102), ALT (p = 0.923), AST (p = 0.986) and MDA (p = 0.055) (Fig. 3A- 
F). 
3.11. Certainty assessment 
The overall certainty of evidence across the studies was graded ac-
cording to the guidelines of the GRADE (Grading of Recommendations 
Assessment, Development, and Evaluation) Working Group. The quality 
of evidence could be classifed into four categories according to the 
corresponding evaluation criteria: high, moderate, low, and very low. 
4. Discussion 
In this meta-analysis, we evaluated the effects of chromium supple-
mentation on blood pressure, BMI, liver function enzymes and MDA in 
patients with T2DM. According to the results derived from this study, 
chromium supplementation may reduce DBP and MDA. However, 
chromium supplementation failed to affect SBP, BMI and liver function 
enzymes. Hypotensive effects of chromium seemed larger in studies 
supplementing higher doses of chromium. Surprisingly, our results 
showed potential beneficial antioxidant effects of chromium in studies 
supplementing lower doses of chromium in patients with T2DM. To the 
best of our knowledge, this is the first systematic review and meta- 
analysis evaluating the effects of chromium supplementation on blood 
pressure, MDA, liver function enzymes and BMI in patients with T2DM. 
Increased blood pressure is a leading risk factor for death and 
disability in patients with T2DM.13,49 Scientific organizations recom-
mend initiating treatment for hypertension in patients with T2DM 
whose blood pressure is more than 140/90 mmHg with a treatment goal 
of SBP less than 140 mmHg and DBP less than 90 mmHg.50,51 Epide-
miological studies suggest that consumption of chromium and plasma 
levels of chromium may play a major role in regulating blood pres-
sure.14,50,52 Our results supported this contention by demonstrating that 
chromium supplementation, especially for higher dose improved blood 
pressure levels by decreasing DBP. Moreover, the present 
meta-regression suggesting that higher chromium dose may associated 
with a better response to SBP. However, potential side effects of 
high-dose of chromium supplementation should be carefully monitored. 
In line with our results, some clinical trial indicated a significant 
reduction in DBP after chromium supplementation.39,43 Moreover, a 
clinical trial of 60 patients with T2DM which examined the impacts of 
chromium supplementation on QTc interval, found no significant 
changes in SBP levels.34 The possible mechanism for hypotensive effects 
of chromium is unclear. It has been shown that low plasma chromium is 
associated with high blood pressure.14 Recently, our meta-analysis of 23 
RCTs showed that chromium supplementation significantly improved 
glycemic profile by decreasing FPG, insulin, HbA1C and HOMA-IR in 
patients with T2DM. Moreover, Rajendran et al. showed that the mean 
serum chromium levels were lower in patients with uncontrolled dia-
betes.53 On the other hand, previous findings suggested that proper 
control of glycemic profile in patients with T2DM may improve blood 
pressure.54,55 Therefore, since chronic hyperglycemia is the primary 
cause of various diabetic complications such as hypertension, hypogly-
cemic supplements such as chromium may improve blood pressure in 
this population. However, animal studies suggested that these effects 
may be related to lower renin-angiotensin system activity, reduced 
angiotensin converting enzyme activity, and increased nitric oxide sys-
tem activity following chromium supplementation.56,57 Moreover, 
chromium can induce its hypotensive effects in patient with T2DM by its 
the potential beneficial antioxidant effects.58,59 It has been suggested 
that oxidative status and intensity of the oxidative stress in diabetic 
patients are higher compared to non-diabetic populations.60 High levels 
of reactive oxygen and nitrogen species are induced in patients with 
diabetes.61 Therefore, the strong implication of reactive oxygen and 
nitrogen species in the etiology of hypertension suggest that antioxi-
dants such as chromium may be effective in the treatment of hyper-
tension.62 However, future mechanistic studies are needed to revealed 
the possible mechanism of the effects of chromium on blood pressure in 
patient with T2DM. 
Previous studies have shown that oxidative stress plays a pivotal role 
in the development of diabetes complications.63 Oxidative stress levels 
are positively associated with an increase in insulin resistance and 
inflammation.64–66 Some studies showed the potential beneficial anti-
oxidant effects of chromium in patients with T2DM. A systematic review 
of 12 studies in 2016 which aimed to evaluate the impacts of chromium 
picolinate supplementation on control of metabolic variables, found that 
chromium supplementation had beneficial effects on oxidative stress 
and inflammatory response in patients with a pathologic status estab-
lished.67 Our finding also showed that chromium supplementation may 
improving oxidative stress by decreasing circulating levels of MDA. The 
possible mechanism for improving MDA levels is unclear. However, 
animal studies showed that MDA-lowering effects of chromium sup-
plementation may be related to its antioxidant features.68,69 As is 
characteristic of diabetic condition, chronic hyperglycemia was linked 
with an increase in oxidative stress. Sundaram et al. revealed that 
chromium picolinate may attenuate hyperglycemia-induced oxidative 
stress in diabetic rat.70 A recently published systematic review of 33 
studies showed that chromium supplementation leads to reducing 
oxidative stress indices such as MDA in diabetes patients.71 Moreover, 
the authors revealed that chromium supplementation markedly in-
creases antioxidant enzymes’ activity and improves levels of antioxidant 
indices in both human and animal studies. Furthermore, it has been 
revealed that chromium decreases oxidative stress by decreasing the 
nitrite serum levels, leading to suppressing the reaction of superoxide 
with nitrite and then reducing peroxynitrite generation.50,72 In addition, 
MDA-lowering effects after chromium intake might be related to the 
inhibition of epinephrine because of the insulinotropic effect of chro-
mium.73 Moreover, chromium supplementation may decrease oxidative 
stress by the activation of glutathione reductase or some other enzymes 
that detoxifies reactive oxygen and nitrogen species.74 Surprisingly, our 
analysis showed that potential beneficial antioxidant effects of chro-
mium have seen in studies supplementing lower doses of chromium in 
patients with T2DM. Regarding optimal dose, further clinical trials 
studies with different dose are needed to confirm our findings. More-
over, the findings of the study should be interpreted with caution 
Table 3 
Overall effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde.   
Number of studies WMD (95 %CI) P within group P heterogeneity I2 
BMI 10 0.08 (− 0.15, 0.31) 0.498 0.662 0.0 % 
SBP 7 − 1.83 (− 4.09, 0.42) 0.111 0.793 0.0 % 
DBP 7 − 2.36 (− 4.13, − 0.60) 0.008 0.268 21.1 % 
ALT 4 2.11 (− 0.69, 4.91) 0.14 0.009 74.3 % 
AST 3 − 0.42 (− 1.39, 0.55) 0.395 0.630 0.0 % 
MDA 8 − 0.55 (− 0.96, − 0.14) 0.008 <0.001 95.0 % 
Abbreviations: CI, confidence interval; WMD, weighted mean differences; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; MDA, malondialdehyde. 
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because of significant heterogeneity. It seems that, the heterogeneity is 
because of clinical baseline heterogeneity, including differences be-
tween sample characteristics of the studies, dissimilar dosages and 
different types of chromium used in the included studies. 
Despite the popularity of chromium as a weight loss supplement, 
there are some controversies about the effects of chromium on 
decreasing body weight and BMI. Some previous studies have been 
suggested that chromium may reduce BMI and increasing insulin 
sensitivity,75 potentiation of the actions of insulin at its receptor 76 
reducing food craving,77 and increasing metabolic rate.78 A 
meta-analyses of 7 RCTs showed that chromium supplementation results 
in statistically significant reductions in body weight and percentage 
body fat without any reduction in BMI, waist circumference or waist to 
hip ratio.79 The results from our analysis find no evidence to support that 
chromium supplementation reduces BMI in patients with T2DM. Body 
mass and BMI loss is not primarily determined by consuming dietary 
supplements, but instead by the number of calories ingested.80 Previous 
investigations did not report any significant changes in calorie intake 
following chromium supplementation, therefore, in agreements with the 
“calories in, calories out” theory, the unchanged caloric intake following 
chromium supplementation corresponded to no changes in BMI. In 
contrast with our findings, a systematic review of 7 RCTs in 2017 which 
assessed the impacts of chromium supplementation in polycystic ovary 
syndrome patients exhibited beneficial effects on reducing BMI.81 It 
should be noted that the findings of the study should be interpreted with 
caution because of low number of included studies and clinically 
insignificant results. Moreover, recent meta-analysis of 19 studies pub-
lished in 2019 showed that chromium supplementation improved 
Fig. 3. A. meta-regression plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of systolic blood pressure. B. 
meta-regression plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of diastolic blood pressure. C. meta- 
regression plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of body mass index. D. meta-regression 
plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of alanine aminotransferase. E. meta-regression 
plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of aspartate aminotransferase. F. meta-regression 
plots of the association between dose of chromium supplementation (μg/day) and weighted mean difference of malondialdehyde. 
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anthropometric indices in subjects with overweight or obesity.82 How-
ever, the effect size was medium and therefore, results remain uncertain. 
These controversies about the effects of chromium supplementation on 
body weight and BMI, may be because of different dose of chromium in 
previous studies. Moreover, the controversies also can be because of the 
different from disease of subjects (polycystic ovary syndrome patients, 
T2DM patients, and subjects with overweight and/or obesity). Based on 
findings of present meta-regression, higher chromium dose may asso-
ciated with better response to obesity in patients with T2DM. 
It is well established that patients with T2DM have a high prevalence 
of liver disease 24–26 and a higher incidence of liver function test ab-
normalities than individuals who do not have diabetes.3 Chen et al. 
exhibited that chromium supplementation inhibited progression of 
NAFLD and improved liver enzymes levels by suppression of inflam-
mation and oxidative stress.83 Furthermore, a clinical trial included 66 
patients suggested a significant decrease in ALT levels in patients with 
type 2 diabetes after chromium supplementation.15 The results from our 
analysis in people with T2DM failed to show efficacy of chromium 
supplementation on improving serum levels of AST and ALT. These 
findings on the effects of chromium supplementation on liver enzymes 
should be interpreted with caution because of low numbers of included 
studies. Further studies are needed to allow for additional evaluation of 
the influence of chromium supplementation on liver function tests in 
patients with T2DM. 
Our current study has important strengths. First, all studies that 
included in our review were high quality, well-designed, randomized, 
double-blinded trials. Second, using Egger’s regression, we did not 
observe any publication bias for studies evaluating the impact of chro-
mium supplementation on BMI, SBP, DBP, and AST. Third, since most of 
the trials lasted ≥ 3 months, our analysis is able to show the long-term 
effects of chromium supplementation on BMI, blood pressure, oxidative 
stress and liver enzymes in patients with T2DM. However, our present 
analysis is not without its limitations. Chromium supplementation was 
used in dissimilar dosages and different types. Moreover, until now, the 
reference range of serum chromium levels are still worthy of discussion, 
especially for patients with T2DM. Furthermore, most included articles 
did not report baseline levels of serum chromium. Therefore, it may be 
difficult to determine which studies investigate the effects of chromium 
in subjects with chromium deficiency. Moreover, chromium adequate 
intake (AI) is 35 μg/day and 25 μg/day for young men and women, 
respectively. In addition, the AI for chromium for ages 51 and older is 
0.2 μg/day 30 μg/day and 20 μg/day for men and women, respectively. 
From all included studies, only 1 studies by Paiva et al. 84 reported the 
dietary intakes of chromium. Therefore, at the present time, it is not 
possible to determine which patients had low serum chromium levels 
and how much of these effects of chromium on blood pressure and MDA 
are attributable to chromium deficiency. Moreover, a significant het-
erogeneity was encountered perhaps due to various regimens, doses, 
duration, center settings, populations enrolled. Calling for cautious 
interpretation of the results. 
This is a serious limitation and should be included because it may 
significantly undermine the validity of results. In terms of publication 
bias, there was significant bias for ALT and MDA. This is a serious lim-
itation and should be included because it may significantly undermine 
the validity of results. In terms of publication bias, there was significant 
bias for ALT and MDA.85,86 Previous investigations showed that mea-
surement of isoprostanes is far superior to measurement of MDA as an 
index of lipid peroxidation and oxidative stress in vivo.87,88 Therefore, 
in terms of evaluating the effects of chromium supplementation on lipid 
peroxidation and oxidative stress, further studies are needed to deter-
mine the effects of chromium on isoprostanes levels. Finally, in most of 
the included studies, blood pressure, BMI, liver function enzymes and 
oxidative stress biomarkers had announced as secondary outcomes. 
Moreover, present study has not been registered in the PROSPERO, this 
could be considered as a limitation as well. 
5. Conclusion 
In conclusion, present systematic review and meta-analysis of all 
available published RCTs up to February 2020 showed that chromium 
supplementation at dose of 200–1000 μg/day may reduce DBP and MDA 
in T2DM patients. However, chromium had no significant effect on SBP, 
BMI and liver function enzymes. Moreover, hypotensive effects of 
chromium seemed larger in higher doses of chromium while anti-
oxidative effects are larger in lower dose. Although our finding suggests 
chromium as a possible therapeutic agent in improving blood pressure 
and MDA, results from long-term trials are needed in order to assess the 
safety of chromium supplements as complementary therapies in the 
management of type 2 diabetes. Therefore, additional long-term and 
high-quality RCTs conducted in individuals with different serum con-
centrations and dietary intakes of chromium are needed to further 
evaluate and confirm these findings. 
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